معرفی
Andrew Tobin is a Professor of Molecular Pharmacology at the University of Glasgow and Director of the Advanced Research Centre. He leads the Centre for Translational Pharmacology, focusing on G protein-coupled receptors (GPCRs) and malaria therapeutics. His research integrates genetic mouse models, chemical biology, and proteomics to develop novel drugs for neurodegenerative diseases and anti-malarials.
Education includes a 1st-class Biochemistry degree from Queen Mary College, University of London, and a D.Phil from the University of Oxford. His career spans industry (Bristol Myers Squibb) and academia (University of Leicester), supported by three Wellcome Trust Senior Research Fellowships.
Research interests:
- GPCR Pharmacology: Mechanisms of receptor signaling, phosphorylation, and allosteric modulation in neurodegeneration (Alzheimer's, prion diseases).
- Malaria Drug Discovery: Targeting essential Plasmodium kinases (e.g., PfCLK3) with covalent inhibitors and probing phospho-signaling pathways.
His publications emphasize GPCR drug design (e.g., M1 muscarinic modulators for cognitive decline) and kinase inhibitors for malaria. Recent work explores biased signaling, receptor oligomerization, and tissue-specific phosphorylation barcoding.
Awards include the Wellcome Trust Senior Research Fellowship (awarded three times).
He leads multidisciplinary teams at the Advanced Research Centre, advancing translational projects from target validation to pre-clinical drug development.
